Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.68 |
| ▸ | ATR | Q13535 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1481026 | 0.93 | PRKCI (0.60) | PRKCIATRMEN1MAPTKMT2A | |
| SCHEMBL1481533 | 0.85 | RAB9A (0.51) | PRKCIMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL27794490 | 0.83 | MAPT (0.46) | PRKCIATRMEN1MAPTKMT2A | |
| SCHEMBL8963872 | 0.83 | NAPRT (0.47) | PRKCIALDH1A1GAANPC1RAB9A | |
| SCHEMBL29965281 | 0.82 | PRKCI (1.00) | PRKCIATRMEN1MAPTKMT2A | |
| SCHEMBL25565213 | 0.82 | PRKCI (1.00) | PRKCIATRMEN1MAPTKMT2A | |
| SCHEMBL8963999 | 0.80 | PRKCI (0.51) | PRKCIMAPTGAANPC1RAB9A | |
| SCHEMBL9007586 | 0.80 | HDAC3 (0.54) | PRKCIMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL13716708 | 0.73 | NPC1 (0.63) | ATRMEN1MAPTKMT2AGAA | |
| SCHEMBL8964314 | 0.72 | HDAC3 (0.54) | MEN1MAPTKMT2AALDH1A1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCI 30/4885ATR 489/4885MEN1 1427/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCI 30/4885ATR 489/4885MEN1 1427/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCI 30/4885ATR 489/4885MEN1 1427/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCI 30/4885ATR 489/4885MEN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.